BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30346831)

  • 1. Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
    Bateman ED; Djukanović R; Castro M; Canvin J; Germinaro M; Noble R; Garin M; Buhl R
    Am J Respir Crit Care Med; 2019 Feb; 199(4):489-495. PubMed ID: 30346831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
    Carr WW; McDonald M; Meizlik P
    Allergy Asthma Proc; 2019 Jul; 40(4):240-249. PubMed ID: 31262379
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
    Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
    Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reslizumab in Eosinophilic Asthma: A Review.
    Deeks ED; Brusselle G
    Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
    Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
    Lam J; Hay JW; Salcedo J; Kenyon NJ
    J Asthma; 2019 Aug; 56(8):872-881. PubMed ID: 30003833
    [No Abstract]   [Full Text] [Related]  

  • 10. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
    Brusselle G; Germinaro M; Weiss S; Zangrilli J
    Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
    Lim HF; Nair P
    Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
    Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
    J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma.
    Wechsler ME; Hickey L; Garin M; Chauhan A
    J Allergy Clin Immunol Pract; 2020; 8(10):3434-3442.e4. PubMed ID: 32562877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
    Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
    Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
    Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
    Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
    Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.